Lucentis

The Food and Drug Administration (FDA) approved LUCENTIS for the treatment of patients with neovascular or wet macular degeneration. LUCENTIS was specifically developed for intraocular use. It has been developed to treat the underlying cause of wet macular degeneration by targeting the molecular pathway that controls the formation of new blood vessels. LUCENTIS is designed to bind and inhibit the vascular endothelial growth factor (VEGF), a protein that is believed to play a critical role in the formation of new blood vessels. VEGF has been shown to lead to wet macular degeneration progression and central vision loss.

LUCENTIS is a series of injections given directly into the eye every four weeks. Your physician will tell you how long you will need to receive the injections.

To learn more about Lucentis, please click on the link below:

http://www.lucentis.com/lucentis/

Lucentis